Clinical Trial Update: A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) [Phase 1]

View source ↗

Summary

Phase 1 dose-finding study of the bromodomain inhibitor birabresib (OTX015/MK-8628) in hematologic malignancies has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• MK-8628 (Birabresib)
• OTX015 (birabresib)
• birabresib (birabresib)

Snippet

Sponsor: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2018-10-01